Saur P, Mühr C, Kazmaier S, Neumann P, Buhre W
Zentrum für Anaesthesiologie, Rettungs- und Intensivmedizin, Georg-August-Universität Göttingen.
Anaesthesiol Reanim. 1996;21(5):131-5.
Postoperative nausea and vomiting (PONV) is still a common perioperative complication and ondansetron has proved to be an effective antiemetic substance in its prevention. The antiemetic effect of single and repetitive application was evaluated in this study. Fifty-one female patients who underwent gynaecological surgical procedures took part in a random double-blind study. Before the start of anaesthesia, 21 patients (group 1) received either a placebo (six patients), 8 mg ondansetron orally (seven patients) or 16 mg orally (eight patients). The remaining 30 patients (group 2), split into subgroups of ten, were given the same preoperative medication as group 1 plus further doses of the same strength 8 and 16 hours after the first intake of the study medication. Metoclopramide was given intravenously if patients had more than one emetic episode or if they asked for it. Nausea and vomiting were documented up to 24 hours after finishing anaesthesia. Metoclopramide had only to be given to patients who had received a placebo. Nausea was felt by 57% (4/7) of the patients after a single dose of 8 mg ondansetron and by 40% (4/10) of the patients after three doses of 8 mg. One patient (14%, 1/7) with a single dose and two patients (20%, 2/10) with a repetitive dose of 8 mg ondansetron vomited. Following a single dose of 16 mg ondansetron, no patient (0/8) had to vomit and 25% (2/8) of the patients had nausea. There were no complications reported by the patients. Ondansetron was shown to be a well-tolerated antiemetic and seems to have a higher reductive effect on PONV when given in a single dose and not repetitively. The prophylaxis of vomiting seems to be more effective than the reduction of nausea. Follow-up studies will have to clarify our findings.
术后恶心呕吐(PONV)仍是常见的围手术期并发症,而昂丹司琼已被证明是预防该并发症的一种有效止吐药物。本研究评估了单次及重复应用昂丹司琼的止吐效果。51例行妇科手术的女性患者参与了一项随机双盲研究。麻醉开始前,21例患者(第1组)分别接受安慰剂(6例患者)、口服8 mg昂丹司琼(7例患者)或口服16 mg昂丹司琼(8例患者)。其余30例患者(第2组)分为每组10例的亚组,给予与第1组相同的术前用药,并在首次服用研究药物8小时和16小时后给予相同剂量的药物。如果患者出现不止一次呕吐发作或主动要求,则静脉注射甲氧氯普胺。记录麻醉结束后24小时内的恶心和呕吐情况。仅对接受安慰剂的患者给予了甲氧氯普胺。单次服用8 mg昂丹司琼后,57%(4/7)的患者感到恶心,服用三次8 mg昂丹司琼后,40%(4/10)的患者感到恶心。单次服用8 mg昂丹司琼的1例患者(14%,1/7)呕吐,重复服用8 mg昂丹司琼的2例患者(20%,2/10)呕吐。单次服用16 mg昂丹司琼后,无患者(0/8)呕吐,25%(2/8)的患者感到恶心。患者未报告并发症。昂丹司琼被证明是一种耐受性良好的止吐药,单次给药而非重复给药时,似乎对PONV有更高的缓解作用。预防呕吐似乎比减轻恶心更有效。后续研究将必须阐明我们的发现。